Summary
The present study was undertaken to elucidate (1) the relationship between plasma concentration of medroxyprogesterone acetate (MPA; Clinovir) administered by the PO and the IM routes; and (2) the relationship between dose and plasma concentration of MPA.
Nineteen patients entered the study. In each patient the plasma concentration was monitored after a single PO and IM administration of MPA at the following dose levels: 100 mg (5 patients), 400 mg (5 patients), 800 mg (5 patients) and 1,200 mg (4 patients). The time interval between PO and the IM administration was 1 week.
The results show (1) a very large interindividual variation in plasma concentration; (2) increasing plasma concentration with both PO and IM dose; (3) after the IM administration plasma levels are steady or increase slightly within the test period; (4) after the oral administration the concentration increases rapidly to reach a peak before 2–7 h and subsequently decreases again, peak concentrations being 2–10 times higher than after IM administration; and (5) within the test periods the plasma concentration x time (0–168 h) is comparable with the two methods of administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cornette JC, Kirton KT, Duncan GW (1971) Measurement of medroxyprogesteroneacetate (Provera) by radioimmunoassay. J Clin Endocrinol 33: 459
De Lena M, Brambilla C, Valagussa P, Bonadonna G (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175
Edquist LE, Johansson EDP (1972) Radioimmunoassay of estrone and estradiol in human and bovine peripheral plasma. Acta Endocrinol (Kbh) 71: 716
Goldenberg IS (1969) Clinical trials of testolactone, medroxyprogesterone-acetate and oxylone acetate in advanced female mammary cancer. A report of the Cooperative Breast Cancer Group. Cancer 23: 109
Klaasen DJ, Rapp EF, Hirte WE (1976) Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women. Cancer Treat Rep 60: 251
Mattsson W (1978) High dose medroxyprogesterone acetate treatment in advanced mammary carcinoma. A phase-II investigation. Acta Radiol Oncol 17: 387
Muggia FM, Cassileth PA, Ochoa M Jr, Flatow FA, Gellhorn A, Hyman GA (1968) Treatment of breast cancer with medroxyprogesterne-acetate. Ann Intern Med 68: 328
Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P (1978) A possible new approach to the treatment of metastatic breast cancer: massive doses on medroxyprogesterone acetate. Cancer Treat Rep 62: 499
Robustelli Della Cuna G, Calciata A, Strada MRB, Bumma C, Campio L (1978) High dose medroxyprogesterone-acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64: 143
Segaloff A, Cunningham M, Rice BF, Weeth JB (1967) Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion. Cancer 20: 1673
Stoll A (1967) Progestin therapy of breast cancer: comparison of agents. Br Med J 3: 338
Victor A, Johansson DB (1976) Pharmacokinetic observations on medroxyprogesteroneacetate administered orally and intravaginally. Contraception 14: 319
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salimtschik, M., Mouridsen, H.T., Loeber, J. et al. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes. Cancer Chemother. Pharmacol. 4, 267–269 (1980). https://doi.org/10.1007/BF00255272
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255272